SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ken Crooks who wrote (131)3/19/1997 10:04:00 AM
From: Bill Tomko   of 834
 
While I remain concerned, I believe the street has mis read, if they read beyond the Bloomberg headline at all, the announced clinical results. I have doubled my postion. My opinion is based upon hte following, 1) HITS trial results next month almost have to be good, basis of thought, History of use overseas, lact of bleeding in current anouncement and results vs Heperin 2) the French patner is running the other half of the current study, please rememmber TXB reported on only thier half of the study, TXB ran dosage legs 1 and 3 while the frencch ran 2 and 4 . IT MAY be possible to STAT. combine the two halfs to achieve sat. significance. Lehamn restated its strong buy ralting and 16 target. I think this co is going to be OK.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News